Recent development and application of virtual screening in drug discovery: An overview

Current Pharmaceutical Design

Volumn 10, Issue 9, 2004, Pages 1011-1033

  Hou, Tingjun ^a   Xu, Xiaojie ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

ADME; Database screening; De novo drug design; Molecular docking; Pharmacophore modeling; Scoring function; Structure based drug design; Virtual screening

Indexed keywords

ALDEHYDE REDUCTASE; BENZAMIDINE DERIVATIVE; BETA LACTAMASE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBONATE DEHYDRATASE; CHYMASE; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DOPAMINE; EFAVIRENZ; FARNESYL TRANS TRANSFERASE; GLYCOSYLTRANSFERASE; GYRASE INHIBITOR; HORMONE RECEPTOR; HYDROLASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; KINESIN; LANOSTEROL; METHYLTRANSFERASE; PHOSPHORIBOSYLTRANSFERASE; PROTEINASE; QUINAZOLINE; RETINOIC ACID RECEPTOR; SERINE PROTEINASE; THYMIDYLATE SYNTHASE;

COMPUTER MODEL; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOXICITY; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SCORING SYSTEM; TIME MANAGEMENT;

COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTATIONAL BIOLOGY; DRUG DESIGN; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 1642350394     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452721     Document Type: Review

References (178)

1. Debouck C, Metdalf B. The impact of genomics on drug discovery. Annu Rev Pharmacol Toxicol 2000; 40: 193-207.
2. Hertzberg RP, Pope AJ. High-throughput screening: new technology for the 21st centrury. Curr Opin Chem Biol 2000; 4: 445-51.
3. Walters WP, Stahl MT, Murcko MA. Virtual screening-an overview. Drug Discov Today 1998; 3: 160-78.
4. Lyne PD Structure-based virtual screening: an overview. Drug Discov Today 2002; 7: 1047-1055.
5. Schneider G, Böhm HJ. Virtual screening and fast automated docking methods. Drug Discov Today 2002; 7: 63-70.
6. Gund P. Three-dimensional Pharmacophore Pattern Searching. Prog Mol Subcell Biol 1977; 5: 117-43.
7. Kurogi Y, Guner OF. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 2001; 8: 1035-55.
8. Langer T, Hoffmanne RD. Virtual screening: an effective tool for lead structure discovery? Curr Pharm Design 2001; 7: 509-27.
9. CATALYST is available from Accelrys, 9685 Scranton Road, San Diego, CA 92121, US.
10. DISCO is available from Tripos Inc 1699 South Hanley Road, St Louis, MO 63144-2913, US.
11. GASP is available from Tripos Inc 1699 South Hanley Road, St Louis, MO 63144-2913, US.
12. Jones G, Willett P, Glen RC. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J Comput Aided Mol Des 1995; 9: 532-49.
13. Structure Based Focusing is available from Accelrys, 9685 Scranton Road, San Diego, CA 92121, US.
14. Böhm HJ The computer program LUDI A new method for the de novo design of enzyme inhibitors. J Comp Aided Mol Des 1992a; 6: 61-79.
15. Böhm HJ LUDI: rule based automatic design of new substituents for enzyme inhibitor leads. J Comp Aided Mol Des 1992b; 6: 593-606.
16. DISCO is available from Tripos Inc. 1699 South Hanley Road, St Louis, MO 63144-2913, USA,
17. ISIS Base, MDL Information Systems, Inc; San Leandro, CA, USA.
18. Chem-X version 96; Oxford Molecular Group, Inc; Hunt Valley, MD 21030, 2001
19. Fox T, Haaksma EEJ. Computer based screening of compound database: 1 preselection of benzamidine-based thrombin inhibitor. J Comput Aided Mol Des 2000; 14: 411-25.
20. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28: 849-57.
21. Hindle SA, Rarey M, Buning C, Lengauer T. Flexible docking under pharmacophore type constraints. J Comput Aided Mol Des 2002; 16: 129-49.
22. Brenk R, Naerum L, Grädler U, Gerber HD, Garcia GA, Reuter K, et al. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on new unexpected binding model detected by crystal structure analysis. J Med Chem 2003; 46: 1133-43.
23. Sakamuri S, Enyedy IJ, Zaman WA, Tella SR, Kozikowski AP, Flippen-Anderson JL, et al. 2,3-disubstituted quinuclidines as a novel class of dopamine transporter inhibitors. Bioorgan Med Chem 2003; 11: 1123-35.
24. Enyedy IJ, Sakamuri S, Zaman WA, Johnson KM, Wang SM. Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. Bioorgan Med Chem Lett 2003; 13: 513-17.
25. Koide Y, Tatsui A, Hasegawa T, Nurakami A, Satoh S, Yamada H, et al. Identification of a stable chymase inhibitor using a pharamcophore-based database search. Bioogan Med Chem Lett 2003; 13: 25-9.
26. Singh J, van Vlijmen H, Liao YS, Lee WC, Cornebise M, Harris M, et al. Identification of potent and novel α4β1 antagonists using in silico screening. J Med Chem 2002; 45: 2988-93.
27. Koide Y, Hasegawa T, Takahashi A, Endo A, Mochizudi N, Nakagawa M, et al. Development of novel EDG3 antagonist using a 3-D database search and their structure-activity relationship. J Med Chem 2002; 45: 4629-38.
28. Schweitzer BA, Loida PJ, CaJacob CA, Chott RC, Colantes EM, Hedge SG, et al. Discovery of imidazole glycerol phosphate dehydrate inhibitor through 3-D database searching. Bioorgan Med Chem Lett 2002; 12: 1743-46.
29. Yamazaki KT, Hasegawa H, Umekawa K, Ueki Y, Ohashi N, Kananoka M. Design, synthesis and biological activity and novel-non-peptidyl endothelin converting enzyme inhibitors, 1-phenyl-terazole-formaza analogues. Bioorgan Med Chem Lett 2002; 12: 1275-78.
30. Kurogi Y, Muyata K, Okamura T, hashimoto K, Tsutsumi K, Nasu M, et al. Discovery of novel messangial cell proliferation inhibitors using a three-dimensional database searching method. J Med Chem 2001; 44: 2304-07.
31. Enyedy IJ, Zaman WA, Sakamuri S, Kozikowski AP, Johnson KM, Wang SM. Pharmacophore-based discovery of 3, 4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors. Bioorgan Med Chem Lett 2001; 11: 1113-18.
32. Chen GS, Chang CS, Kan WM, Chang CL, Wang KC, Chern JW. Novel lead generation through hypothetical pharmacophore three-dimensional database searching: discovery of isoflavonoids as nonsterioidal inhibitors of Rat 5α-reductase. J Med Chem 2001; 44: 3759-63.
33. Huang P, Loew GH, Fonamizu H, Mimura M, Ishiyama N, Hayashida M, et al. Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. J Med Chem 2001; 44: 4082-91.
34. Hiramatsu Y, Tsukida T, Nakai Y, Inoue Y, Kondo H. Study on selection blocker 8 lead discovery of non-sugar antagonists using a 3D-pharmacophore model. J Med Chem 2000; 43: 1476-83.
35. Langer T, Hoffmann A. Virtual screening: an effective tool for lead structure discovery? Curr Pharm Des 2001; 7: 509-27.
36. Murcko M. Recent advances in ligand design methods; Reviews in Computational Chemistry Vol 11; Edited by Lipkowitz KB and Boyd DB Wiley-VCH inc, 1997; 1-66.
37. LUDI is available from Accelrys, 9685 Scranton Road, San Diego, CA 92121, USA.
38. Leapfrog is available from Tripos Inc 1699 South Hanley Road, St Louis, MO 63144-2913, USA.
39. Sprout is available from SimBioSym In 135 Queen's Plate Drive Unit 355 Toronto, Ontario M9W 6V1, Canada.
40. Gillet VJ, Myatt G, Zsoldos Z, Johnson AP. SPROUT, HIPPO and CAESA: Tools for de novo structure generation and estimation of synthetic accessibility. Perspect Drug Discov Design 1995; 3: 34-50.
41. Mata P, Gillet VJ, Johnson AP, Lampreia J, Myatt GJ, Sike S, et al. SPROUT-3D structure generation using templates. J Chem Inf Comput Sci 1995; 35: 479-93.
42. Lauri G, Barlett PA. CAVEAT: a program to facilitate the design of organic molecules. J Comput Aided Mol Des 1994; 8: 51-66.
43. Ho CMW, Marshall GR. Cavity search: an algorithm for the isolation and display of cavity-like binding regions. J Comput Aided Mol Des 1990; 4: 337-54.
44. Ho CM, Marshall GR. FOUNDATION: a program to retrieve all possible structures containing a user-defined minimum number of matching query elements from three-dimensional databases. J Comput Aided Mol Des 1993; 7: 623-47.
45. Ho CM, Marshall GR. DBMAKER: a set of programs designed to generate three-dimensional databases based upon user-specific criteria, J Comput Aided Mol Des 1995; 9: 65-86.
46. Ho CM, Marshall GR. SPLICE: a program to assemble partial query solution from three-dimensional database searches into novel ligands. J Comput Aided Mol Des 1993; 7: 623.
47. Lawrence MC, Davis PC. CLIX: a search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure. Proteins: Struct Funct Genet 1992; 12: 31-41.
48. Pearlman DA, Murcko MA. CONCEPTS: new dynamics algorithm for de novo drug suggestions. J Comput Aided Mol Des 1993; 14: 1184.
49. Pearlman DA, Murcko MA. CONCERTS: dynamics connection of fragments as an approach to De novo ligand design. J Comput Aided Mol Des 1996; 39: 1651-63.
50. Miranker A, Karplus M. An automated-method for dynamic ligand design. Proteins: Struct Funct Genet 1995; 23: 472-90.
51. Rotstein SH, Murcko MA. GenStar: a method for de novo drug design. J Comput Aided Mol Des 1993; 7: 23-43.
52. Rotstein SH, Murcko MA. GroupBuild: a fragment-based method for de novo drug design. J Med Chem 1993; 36: 1700-10.
53. Moon J, Howe W. Computer design of bioactive molecules: a method for receptor-based de novo ligand design. Proteins 1991; 11: 314-28.
54. Bohacek RS, McMartin C. Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J Am Chem Soc 1994; 116: 5560-71.
55. Eisen MB, Wiley DC, Karplus M, Hubbard RE. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 1994; 19: 199-221.
56. Douguet D, Thoreau E, Grassy GA. Genetic algorithm for the automated generation of small organic molecules: drug design using an evolutionary algorithm, J Comput Aided Mol Des 2000; 14: 449-66.
57. Nishibata Y, Itai A. Automatic creation of drug candidate structures based on receptor structure-starting point for artificial lead generation. Tetrahedron 1991; 47: 8985-90.
58. Nishibata Y, Itai A. Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. J Med Chem 1993; 36: 2921-28.
59. Gehlaar DK. De novo design of enzyme inhibitors by Monte Carlo ligand generation. J Med Chem 1995; 38: 466-72;
60. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991; 11: 29-34.
61. Tschinke V, Cohen NC. The NEWLEAD program: a new method for the design for the design of candidate structures from pharmacophoric hypotheses. J Med Chem 1993; 36: 3863-70.
62. Clark DE, Frenkel D, Levy SA, Li J, Murray CW, Robson B, et al. PROGAND: an approach to de novo drug design. J Comput Aided Mol Des 1995; 9: 13-32.
63. DeWitte R. SMOG, de novo design method based on simple, fast, and accurate free energy estimates 2 case studies in molecular design. J Am Chem Soc 1997; 119: 4608-17.
64. Schneider G, Lee ML, Stahl M, Schneider P. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J Comput Aided Mol Des 2000; 14: 487-94.
65. Ji TT, Zhang WN, Zhang M, Kudo M, Aoyama Y, Yoshida Y, et al. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol l4α-demethylase of fungi. J Med Chem 2003; 46: 474-85.
66. Liebeschuetz JW, Jones SD, Morgan PJ, Murray CW, Rimmer AD, Roscoe JME, et al. PROLECT: combining structure-based drug design and array-based chemistry for rapid lead discovery 2 the development of a series of highly potent and selective factor Xa inhibitors. J Med Chem 2002; 45: 1221-32.
67. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K, et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 2001; 44: 4615-27.
68. Boehm HJ, Boehringer M, Bur D, Gmuender H, Huber W, Klaus W, et al. Novel inhibitors of DNA gyrase: 3-D structure based biased needle screening, hit validation by biophysical methods, and 3-D guided optimization A promising alternative to random screening. J Med Chem 2000; 43: 2664-74
69. Hou TJ, Wang JM, Chen LR, Xu XJ. Automatic docking of peptides and proteins using a hybrid method combined with genetic algorithm and tabu search. Protein Eng 1999; 12: 639-47.
70. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 40: search strategies for automated molecular docking of flexible molecule database. J Comput Aided Mol Des 2001; 15: 411-28.
71. Zsoldos Z, Johnson AP, Simon A, Szabo I, Szabo Z. eHiTS: Novel algorithm for fast, exhaustive flexible ligand docking and scoring, Presentation at the: 224th ACS National Meeting, Boston, MA, USA, 2002.
72. Pang YP, Perola E, Xu K, Predergast FG. EDUDOC: a computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases. J Comput Chem 2001; 22: 1750-71.
73. Rarey M, Kramer B, Lengauer T, Klebe GA. Fast Flexible Docking Method using an Incremental Construction Algorithm. J Mol Biol 1996; 261: 470-89.
74. ICM is available from MolSoft LLC, 3366 North Torrey Pines Court Suite 300 La Jolla, CA 92037, USA.
75. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graphics Mol Mod 2003; 21: 289-307.
76. Fred is available from OpenEye Inc, 3600 Cerrillos Rd, Suite 1107 Santa Fe, NM 87507, USA.
77. FlexiDock is available from Tripos Inc 1699 South Hanley Road, St Louis, MO 63144-2913, USA.
78. Schnecke V, Kuln LA. Virtual screening with solvation and ligand-induced complementarity. Perspect Drug Des Discov 2000; 20: 171-90.
79. Affinity is available from Accelrys, 9685 Scranton Road, San Diego, CA 92121, USA.
80. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of Autodock 2.4. J Comput Aided Mol Des 1996; 10: 293-304.
81. Glide is available from Schrödinger, 1500 SW First Avenue, Suite 1180, Portland.
82. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and Validation of a Genetic Algorithm for Flexible Docking. J Mol Biol 1997; 267: 727-48.
83. McMartin C, Bohacek RS. QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 1997; 11: 333-44.
84. Hou TJ, Zhu LL, Chen LR, Xu XJ. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies. J Chem Inf Comput Sci 2003; 43: 273-87.
85. Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002; 46: 34-40.
86. Claussen H, Buning C, Rarey M, Lengauer T. FlexE: efficient molecular docking considering protein structure variations. J Mol Biol 2001; 308: 377-95.
87. Grünber S, Stubbs M, Klebe G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J Med Chem 2002; 45: 3588-02.
88. Grüneberg S, Wendt B, Klebe G. Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II. Angew Chem Int Ed Engl 2001; 40: 389-93.
89. Power RA, Morandi F, Shoichet BK. Structure-based discovery of a novel nonvalent inhibitor of AmpC β-lactamase. Structure 2002; 10: 1013-23.
90. Ilno M, Furugori T, Mori T, Moriyama. S, Fukuzawa A, Shibano T, Rational design of new lead compounds: structures for selective βARK1 inhibitors. J Med Chem 2002; 45: 2150-59.
91. Costi MP, Tondi D, Rinald M, Barlocco D, Pecorari P, Soragni F, et al. Structure-based studies on specifies-specific inhibition of thymidylate synthase. BBA-Mol Basis Dis 2002; 1587: 206-14.
92. Rastelli G, Ferrari AM, Costantino L, Gamberini MC. Discovery of new inhibitors of aldose reductase from molecular modeling and database searching. Bioorgan Med Chem 2002; 10: 1437-50.
93. Pang YP, Xu K, Kollmeyer TM, Perola E, McGrath WJ, Green DT, et al. Discovery of a new inhibitor lead of adenovirus proteinase: steps towards selective, irreversible inhibitors of cysteine proteinases. FEBS Lett 2001; 502: 93-97.
94. Enyedy I, Ling Y, Nacro K, Tomita Y, Wu XH, Cao YY, et al. Discovery of small molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44: 4313-24.
95. Iwata Y, Arisawa M, Hamada R, Kita Y, Mizutani MY, Tomioda N, et al. Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis. J Med Chem 2001; 44: 1718-28.
96. Enyedy IJ, Lee SL, Kuo AH, Dickson RB, Lin CY, Wang S. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J Med Chem 2001; 44: 1349-55.
97. Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 2000; 97: 1008-13.
98. Paiva AM, Vanderwall DE, Blanchard JS, Kozarich JW, Williamson JM, Kelly TM. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of mycobacterium tuberculosis. BBA 2001; 1545: 67-77.
99. Perola E, Xu K, Kollmeyer TM, Kaufmann SH, Predergast FG, Pang YP. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J Med Chem 2000; 43: 401-08.
100. Sarmiento M, Wu L, Keng YF, Song L, Luo ZW, Huang ZW, et al. Structure-based discovery of small inhibitors targeted to protein tyrosine phosphatase 1B. J Med Chem 2000; 3: 146-55.
101. Hopkins SC, Vale RD, Kuntz ID. Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 2000; 39: 2805-18.
102. Aronov AM, Munagala NR, Ortizde Montellano PR, Kuntz ID, Wang CC. Rational design of selective submicromolar inhibitors of tritrichomonas foetus hypoxanthine-guainine-xanthine phosphoribosyltransferase. Biochemistry 2000; 39: 4684-91.
103. Freymann DM, Wenck MA, Engel JC, Feng J, Focia PJ, Eakin AE, et al. Efficient identification of inhibitors targeting the close active site conformation of the HPRT from trypanosoma cruzi. Chem Biol 2000; 7: 957-68.
104. Makino S, Kayahara T, Tashiro K, Takahashi M, Tsuji T, Shoji M. Discovery of a novel serine protease inhibitor utilizing a structure-based and experimental selection of fragments technique. J Comput Aided Mol Des 2000; 15: 553-59.
105. Filikov AV, Mohan V, Vickers TA, Griffey RH, Cook PD, Abagyan RA, et al. Identification of ligands for RNA targets via structure-based virtual screening: HIV TAR. J Comput-Aided Mol Des 2000; 14: 593-610.
106. Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 2000; 93: 1008-13.
107. Gohlke H, Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed 2002; 41: 2644-76.
108. Grzybowski BA, Ishchenko AV, Shimada J, Whitesides GM, Shakhnovich EI. From knowledge-based potentials to combinatorial lead design in silico. Acc Chem Res 2002; 5: 261-69.
109. Ishchenko AV, Shakhnovich EI. Small molecule growth (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions. J Med Chem 2002; 45: 2770-80.
110. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem 1999; 42: 791-804.
111. Mitchell JBO, Laskowski RA, Alex A, Thornton JM. BLEEP-potential of mean force describing protein-ligand interactions: I Generating potential. J Comput Chem 1999; 20: 1165-76.
112. Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 2000; 20: 337-56.
113. Gohlke H, Hendlich M, Klebe G. Predicting binding modes, binding affinities and 'hot spots' for protein-ligand complexes using a knowledge-based scoring function. Perspect Drug Discovery Des 2000; 20: 115-44.
114. Verkhiver G, Appelt K, Freer ST, Villafrancda JE. Empirical free energy calculations of protein-ligand crystallographic complexes I knowledge-based ligand-protein interaction potentials applied to the prediction of human immunodeficiency virus 1 protease binding affinity. Protein Eng 1995; 8: 677-91.
115. Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42: 5100-09.
116. Hendlich M. Databases for protein-ligand complexes. Acta Crystallogr 1998; D54: 1178-82.
117. Sotriffer CA, Gohlke H, Klebe G. Docking into knowledge-based potential fields: a comparative evaluation of DrugScore. J Med Chem 2002; 45: 1967-70.
118. Ischchenko AV, Shakhnovich EI. Small molecular growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions. J Med Chem 2002; 45: 2770-80.
119. Shoichet BK, Leach AR, Kuntz ID. Ligand solvation in molecular docking. Proteins 1999; 34; 4-16.
120. Zou X, Sun Y, Kuntz ID. Inclusion of solvation in ligand binding free energy calculations using the generalized-Born model. J Am Chem Soc 1999; 121: 8033-43.
121. Donini OAT, Kollman PA. Calculation and prediction of binding free energies for the matrix metalloproteinases. J Med Chem 2000; 43: 4180-88.
122. Kuhn B, Kollman PA. Binding of a diverse set of ligands to avidin and streptavidin: An accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J Med Chem 2000; 43: 3786-91.
123. Srinvasan J, Cheatham TE, Cieplak P, Kollman PA, Case DA. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate - DNA helices. J Am Chem Soc 1998; 120: 9401-509.
124. Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH, Chong L, et al. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc Chem Res 2000; 33: 889-97.
125. Wang JM, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001; 123: 5221-30.
126. Charifson PS, Corkerey JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42: 5100-09.
127. CScore is available from Tripos Inc 1699 South Hanley Road, St Louis, MO 63144-2913, USA.
128. Jones G, Willett P, Glen R, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-48.
129. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interactions: A simplified potential approach. J Med Chem 1999; 42: 791-804.
130. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982; 161: 269-88.
131. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions 1 The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997; 11: 425-45.
132. Rarey M, Kramer B, Lengauer T, Klebe GA. fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261: 470-89.
133. Clark RD, Strizhev A, Leonard JM, Blake JF, Matthew JB. Consensus scoring for ligand/protein interactions. J Mol Graph Mod 2002; 20: 281-95.
134. Paul N, Rognan D, ConsDock: A new program for the consensus analysis of protein-ligand interactions. Proteins 2002; 47: 521-33.
135. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
136. Lipinski CA. Druglike properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-49.
137. Stenberg P, Luthman K, Artursson P. Virtual screening of intestinal drug permeability. J Control Release 2000; 65: 231-43.
138. Stenberg P, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 2001; 44: 1927-37.
139. Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Bio 2001; 5: 452-63.
140. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA. Present and further in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 2000; 44: 313-24.
141. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 2001; 44: 251-272.
142. Ekins S, Wrighton SA. Application of in silico approaches to predicting drug-drug interactions. J Pharmacol Toxicol Methods 2001; 45: 65-9.
143. Beresford AP, Selick HE, Tarbit MH. The emerging importance of predictive ADME simulation in drug discovery. Drug Disc Today 2002; 7: 109-16.
144. Boobis A, Gundert-Remy U, Kremers P, Macheras P, Pelkonen O. In silico prediction of ADME and pharmacokinetics - Report of an expert meeting organised by COST B15. Eur J Pharm Sci 2002; 17: 183-93.
145. van de Waterbeemd H, Gifford E. ADMET in silico modeling: towards prediction paradise? Nat Rev Drug Discov 2003; 2: 192-204.
146. Cruciani G, Crivori P, Carrupt PA, Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. Theochem 2000; 53: 17-30.
147. Hou TJ, Xu XJ. ADME Evaluation in Drug Discovery: applications of genetic algorithms on the prediction of blood-brain partitioning of a large set drugs. J Mol Model 2002; 8: 337-49.
148. Wessel MD, Jurs PC, Tolan JW, Muskal SM. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Info Comp Sci 1998; 38: 726-35.
149. Doniger S, Hofmann T, Yeh J. Predicting CNS permeability of drug molecules: comparison of neural network and support vector machine algorithms. J Comput Biol 2002; 9: 849-64.
150. Ghuloum AM, Sage CR, Jain AN. Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules. J Med Chem 1999; 42: 1739-48.
151. Yoshica F, Toplss JG. QSAR model for drug human oral bioavailability. J Med Chem 2000; 43: 2575-85.
152. Andrews CW, Bennett L, Yu LX Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship Pharm Res 2000; 17: 639-44.
153. Bains W, Gilbert R, Sviridenko L, Gascon JM, Scoffin R, Birchall K, et al. Evolutionary computational methods to predict oral bioavailability QSPRs. Curr Opin Drug Disc Dev 2002; 5: 44-51.
154. Mandagere AK, Thompson TN, Hwang KK. A graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 2002; 45: 304-11.
155. Ayrton A, Morgan P. The role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469-97.
156. Wiese M, Pajeva IK. Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 2001; 8: 685-713.
157. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31-40.
158. Österberg T, Norinder U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 2000; 10: 295-303.
159. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuectz EG, Lan LB, et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 2002; 61: 964-73.
160. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PDJ. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 2002; 45: 1737-40.
161. Pajeva IK, Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis), J Med Chem 2002; 45: 5671-86.
162. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three- and four-dimensional quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 2000; 28: 994-1002.
163. Ekins S, De Groot M, Jones JP. Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modelling cytochrome P450 active sites. Drug Metab Dispos 2001; 29: 936-44.
164. Cruciani G. Abstract presented at Euro QSAR, 2002.
165. Zuegge J, Fechner U, Roche O, Parratt NJ, Engkvist O, Schneider G. A fast virtual screening filter for cytochrom450 3A4 inhibition liability of compound libraries. QSAR 2002; 21: 249-56.
166. Langowski J, Long A. Computer systems for the prediction of xenobiotic metabolism. Adv Drug Delivery Rev 2002; 54: 407-15.
167. Ehrhardt PW. Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development, IUPAC, Blackwell Science, Malden, Massachussetts, 1999.
168. VolSurf is available from Tripos Inc 1699 South Hanley Road, St Louis, MO 63144-2913, USA.
169. Egan WJ, Merz KM Jr, Baldwin JJ. Prediction of Drug Absorption Using Multivariate Statistics. J Med Chem 2000; 43: 3867-77.
170. C2ADME is available from Accelrys, 9685 Scranton Road, San Diego, CA 92121, USA.
171. Duffy EM, Jorgensen WL. Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 2000; 122: 2878-88.
172. Jorgensen WL, Duffy EM. Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 2000; 10: 1155-58.
173. QikProp is available from Schrödinger, 1500 SW First Avenue, Suite 1180 Portland, OR 97201, USA.
174. Greene N. Computer systems for the prediction of toxicity: an update. Adv Drug Deliv Rev 2002; 54: 417-31.
175. Durham SK, Pearl GM. Computational methods to predict drug safety liabilities. Drug Disc Dev 2001; 4: 110-15.
176. Jiang S, Zhao Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Design 2002; 8(8): 563-80.
177. Langer T, Hoffmann RD. Virtual screening: an effective tool for lead structure discovery? Curr Pharm Design 2001; 7(7): 509-27.
178. Mason JS, Good AC, Martin EJ. 3-D pharmacophores in drug discovery. Curr Pharm Design 2001; 7(7): 567-97.